1
|
Foret T, Dufrost V, Heymonet M, Risse J, Faure GC, Louis H, Lagrange J, Lacolley P, Devreese K, Gibot S, Regnault V, Zuily S, Wahl D. Circulating Endothelial Cells are Associated with Thromboembolic Events in Patients with Antiphospholipid Antibodies. Thromb Haemost 2023; 123:76-84. [PMID: 35977699 DOI: 10.1055/a-1926-0453] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Endothelial damage has been described in antiphospholipid antibody (aPL)-positive patients. However, it is uncertain whether circulating endothelial cells (CECs)-which are released when endothelial injury occurs-can be a marker of patients at high risk for thrombosis. METHODS Ninety-seven patients with aPL and/or systemic lupus erythematosus (SLE) were included. CECs were determined by an automated CellSearch system. We also assayed plasma levels of tissue factor-bearing extracellular vesicles (TF+/EVs) and soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) as markers of endothelial dysfunction/damage. RESULTS Patients' mean age was 46.1 ± 13.9 years, 77 were women. Thirty-seven had SLE and 75 patients were suffering from antiphospholipid syndrome. Thirty-seven percent of patients presented a medical history of arterial thrombosis and 46% a history of venous thromboembolism (VTE). Thirteen patients had increased levels of CECs (>20/mL), with a mean CEC level of 48.3 ± 21.3 per mL. In univariate analysis, patients with obesity or medical history of myocardial infarction (MI), VTE, or nephropathy had a significant increased CEC level. In multivariate analysis, obesity (odds ratio [OR] = 6.07, 95% confidence interval [CI]: 1.42-25.94), VTE (OR = 7.59 [95% CI: 1.38-41.66]), and MI (OR = 5.5 [95% CI: 1.1-26.6)] were independently and significantly associated with elevated CECs. We also identified significant correlations between CECs and other markers of endothelial dysfunction: sTREM-1 and TF+/EVs. CONCLUSION This study demonstrated that endothelial injury assessed by the levels of CECs was associated with thromboembolic events in patients with aPL and/or autoimmune diseases.
Collapse
Affiliation(s)
- Thomas Foret
- INSERM, DCAC, Université de Lorraine, Nancy, France.,Division of Vascular Medicine, CHRU-Nancy, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
| | - Virginie Dufrost
- INSERM, DCAC, Université de Lorraine, Nancy, France.,Division of Vascular Medicine, CHRU-Nancy, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
| | | | - Jessie Risse
- INSERM, DCAC, Université de Lorraine, Nancy, France.,Division of Vascular Medicine, CHRU-Nancy, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France.,CH de Sarreguemines, Sarreguemines, France
| | - Gilbert C Faure
- Laboratory of Immunology, CHRU-Nancy, Nancytomique, Pôle Laboratoire.,CRAN UMR CNRS 7039, Nancy, France
| | | | - Jeremy Lagrange
- INSERM, DCAC, Université de Lorraine, Nancy, France.,Délégation à la Recherche Clinique et à l'Innovation, CHRU-Nancy, Nancy, France
| | - Patrick Lacolley
- INSERM, DCAC, Université de Lorraine, Nancy, France.,Délégation à la Recherche Clinique et à l'Innovation, CHRU-Nancy, Nancy, France
| | - Katrien Devreese
- Department of Diagnostic Sciences, Coagulation Laboratory, Ghent University Hospital, Ghent University, Ghent, Belgium
| | | | - Veronique Regnault
- INSERM, DCAC, Université de Lorraine, Nancy, France.,Délégation à la Recherche Clinique et à l'Innovation, CHRU-Nancy, Nancy, France
| | - Stéphane Zuily
- INSERM, DCAC, Université de Lorraine, Nancy, France.,Division of Vascular Medicine, CHRU-Nancy, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
| | - Denis Wahl
- INSERM, DCAC, Université de Lorraine, Nancy, France.,Division of Vascular Medicine, CHRU-Nancy, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
| |
Collapse
|
2
|
Loiseau P, Foret T, DeFilippis EM, Risse J, Etienne AD, Dufrost V, Moulinet T, Erkan D, Devilliers H, Wahl D, Zuily S. Risk of livedo with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Lupus 2022; 31:1595-1605. [DOI: 10.1177/09612033221126852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background Livedo is a well-known skin condition in patients with systemic lupus erythematosus (SLE) which correspond to small vessels involvement. The influence of antiphospholipid antibodies (aPL) on the occurrence of livedo is controversial. The aim of our study was to estimate the risk of livedo associated with aPL in patients with SLE. Methods We conducted a systematic review and meta-analysis of the literature from 1977 to 2021 to estimate the risk of livedo in SLE patients according to different aPL profiles. Data sources were PubMed, Embase, Cochrane Library, hand search, and reference lists of studies. Studies were selected if they included SLE patients with descriptions of the exposure to aPL and the outcome ( livedo). Two independent investigators assessed study eligibility, quality, and extracted patient characteristics from each study as well as exposure (aPL) and outcome ( livedo). Risk estimates were pooled using random effects models and sensitivity analyses. For all stages of the meta-analysis, we followed the PRISMA guidelines. PROSPERO registration number: CRD42015027377. Results Of the 2,355 articles identified, 27 were included with a total of 4,810 SLE patients. The frequency of livedo was 25.5% in aPL-positive patients and 13.3% in aPL-negative patients. The overall Odds Ratio (OR) for livedo in aPL-positive patients compared to aPL-negative patients was 2.91 (95% CI; 2.17–3.90). The risk of livedo was significantly increased for most of aPL subtypes, including lupus anticoagulant (LA) (OR = 4.45 [95% CI; 2.21–8.94]), IgG anticardiolipin (OR = 3.95 [95% CI; 2.34–6.65]), and IgG anti-β2-glycoprotein 1 (OR = 3.49 [95% CI; 1.68–7.27]). Conclusions We demonstrated in this meta-analysis an excess risk of livedo in aPL-positive SLE patients compared to aPL-negative patients. For daily practice, in patients with SLE, livedo associated with aPL could correspond to a peculiar group of patients with small vessel disease. Livedo could be a good candidate for inclusion in future classification criteria for antiphospholipid syndrome.
Collapse
Affiliation(s)
- Pierre Loiseau
- CHU Amiens-Picardie, Department of Internal Medicine, Amiens, France
| | - Thomas Foret
- CHU de Besançon, Vascular Medicine Unit, Vascular Surgery Department, Besançon, France
| | | | | | - Anais D Etienne
- Department of Internal Medicine, CHRU de Nancy, Nancy, France
| | - Virginie Dufrost
- Université de Lorraine, Nancy, France
- Vascular Medicine Division And Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France
| | - Thomas Moulinet
- Department of Internal Medicine, CHRU de Nancy, Nancy, France
| | - Doruk Erkan
- Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, NY, USA
| | - Hervé Devilliers
- CHRU de Dijon, Department of Internal Medicine, Regional Competence Centre For Systemic Autoimmune Diseases, Dijon, France
| | - Denis Wahl
- Université de Lorraine, Nancy, France
- Vascular Medicine Division And Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France
| | - Stéphane Zuily
- Université de Lorraine, Nancy, France
- Vascular Medicine Division And Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France
| |
Collapse
|
3
|
Chock EY, Domingues V, Dufrost V, Risse J, Seshan SV, Barbhaiya M, Sartelet H, Erkan D, Wahl D, Zuily S. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Clin Exp Rheumatol 2022; 21:103158. [PMID: 35907609 DOI: 10.1016/j.autrev.2022.103158] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Accepted: 07/24/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Microvascular renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their association with aPL is inconsistent among studies. Therefore, our objective was to investigate associations between microvascular renal lesions and aPL among systemic lupus erythematosus (SLE) patients. METHODS Studies were selected if they included SLE patients with and without aPL positivity with a description of kidney biopsy identifying acute and/or chronic microvascular renal lesions as well as lupus nephritis. Data sources were Pubmed, Embase, Cochrane Library, hand search, congress abstracts, and reference lists of studies, without language restrictions. Risk estimates were independently extracted by 2 investigators. Pooled effect estimates were obtained by using the Mantel-Haenszel method (random effects). RESULTS Of 1860 identified records obtained between 1991 and 2021, 35 published studies (10 cohorts, 7 case-control, 18 cross-sectional) met inclusion criteria, including 3035 SLE patients according to American College of Rheumatology criteria and 454 cases of microvascular renal lesions. Frequency of microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 31.3% vs. 10.4%, respectively. The overall pooled odds ratios (OR) for microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 3.03 (95% confidence interval [CI], 2.25-4.09). The risk of microvascular renal lesions was the highest for lupus anticoagulant (OR = 4.84 [95% CI, 2.93 to 8.02]) and IgG anticardiolipin antibodies (OR = 3.12 [95% CI,1.08-9.02]) while the association with anti-β2-glycoprotein I antibodies (OR = 1.88 [95% CI, 0.25-14.14]) did not reach statistical significance. Furthermore, aPL were not associated with any classes of lupus nephritis. CONCLUSION In SLE patients, aPL-positivity is associated with a significant 3- to 5-fold increased risk for specific microvascular renal lesions. This risk is mainly driven by lupus anticoagulant and IgG anticardiolipin antibodies. Our results support the inclusion of microvascular renal lesions as new criteria for definite antiphospholipid syndrome.
Collapse
Affiliation(s)
| | | | - Virginie Dufrost
- Université de Lorraine, Inserm, DCAC and CHRU-Nancy, Vascular Medicine Division and Regional Competence Center for Rare Auto-Immune Diseases, Nancy, France
| | - Jessie Risse
- Université de Lorraine, Inserm, DCAC and CHRU-Nancy, Vascular Medicine Division and Regional Competence Center for Rare Auto-Immune Diseases, Nancy, France
| | - Surya V Seshan
- Department of Pathology, Weill-Cornell Medical Center/New York Presbyterian Hospital, New York, NY, USA
| | - Medha Barbhaiya
- Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA
| | | | - Doruk Erkan
- Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA
| | - Denis Wahl
- Université de Lorraine, Inserm, DCAC and CHRU-Nancy, Vascular Medicine Division and Regional Competence Center for Rare Auto-Immune Diseases, Nancy, France
| | - Stephane Zuily
- Université de Lorraine, Inserm, DCAC and CHRU-Nancy, Vascular Medicine Division and Regional Competence Center for Rare Auto-Immune Diseases, Nancy, France.
| |
Collapse
|
4
|
Roggel A, Hendricks S, Dykun I, Balcer B, Al-Rashid F, Risse J, Kill C, Totzeck M, Rassaf T, Mahabadi AA. Regional wall motion abnormalities predict culprit lesions in patients presenting with acute chest pain. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Current ESC guidelines for non-ST-segment elevation myocardial infarction suggest the utilization of echocardiography in patients with inconclusive initial electrocardiography and cardiac enzymes. Besides detection of alternative pathologies associated with chest pain, echocardiography can screen for wall motion abnormalities (WMA) as sign of myocardial necrosis.
Purpose
We evaluated the ability of the assessment of regional WMA, detected via transthoracic echocardiography, to predict the presence of culprit lesions in patients presenting with acute chest pain to the emergency department.
Methods
In this prospective single-centre observational cohort study, we included consecutive patients presenting to the emergency department of our University Hospital with acute chest pain, suggestive of an acute coronary syndrome, between December 2018 and August 2020. Patients with ST-elevation myocardial infarction, hemodynamic instability, or known coronary artery disease were excluded. As part of initial workup, patients received bedside echocardiography for the assessment of regional WMA by a dedicated study physician, blinded to all patients' characteristics. The primary endpoint was defined as the presence of culprit lesions as detected in subsequent invasive coronary angiography, requiring coronary revascularization therapy. Logistic regression analysis was performed in different models adjusted for traditional cardiovascular risk factors, cardiac biomarkers as well as established risk scores. Area under the receiver operating characteristics curve (AUC) was calculated to assess a potential improvement in the prediction of culprit lesions.
Results
Overall, 657 patients (age 58.06±18.04 years, 53% male) were included in our study. WMA were detected in 76 patients (11.6%). Patients with WMA were older (66.92±13.85 vs. 56.90±18.21 years, p<0.001), had significantly higher Troponin-levels (18.5 [6.0; 91.5] vs. 6.0 [6.0; 15.0], p<0.001) and higher blood pressure (139.0±19.29 vs. 135.1±19.21, p=0.04). WMA were significantly more frequent in patients reaching the primary endpoint (26.2% vs. 7.6%, p<0.001). In multivariable regression analysis, the presence of WMA was associated with 3-fold increased odds of the presence of culprit lesions (3.41 [1.99–5.86], p<0.001). Adding WMA to a multivariable model containing the TIMI risk score, cardiac biomarkers and traditional risk factors significantly improved the AUC for prediction of obstructive coronary artery disease (0.777 to 0.804, p=0.009).
Conclusion
WMA strongly and independently predict the presence of culprit lesions in patients presenting with acute chest pain to the emergency department. Our results suggest that routine bedside echocardiography for assessment of WMA in emergency department may improve diagnostic algorithms in suspected acute coronary syndrome.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Roggel
- University of Duisburg-Essen - West-German Heart and Vascular Center, Essen, Germany
| | - S Hendricks
- University of Duisburg-Essen - West-German Heart and Vascular Center, Essen, Germany
| | - I Dykun
- University of Duisburg-Essen - West-German Heart and Vascular Center, Essen, Germany
| | - B Balcer
- University of Duisburg-Essen - West-German Heart and Vascular Center, Essen, Germany
| | - F Al-Rashid
- University of Duisburg-Essen - West-German Heart and Vascular Center, Essen, Germany
| | - J Risse
- University Hospital of Essen (Ruhr), Center of Emergency Medicine, Essen, Germany
| | - C Kill
- University Hospital of Essen (Ruhr), Center of Emergency Medicine, Essen, Germany
| | - M Totzeck
- University of Duisburg-Essen - West-German Heart and Vascular Center, Essen, Germany
| | - T Rassaf
- University of Duisburg-Essen - West-German Heart and Vascular Center, Essen, Germany
| | - A A Mahabadi
- University of Duisburg-Essen - West-German Heart and Vascular Center, Essen, Germany
| |
Collapse
|
5
|
Hendricks S, Roggel A, Dykun I, Balcer B, Al-Rashid F, Totzeck M, Risse J, Kill C, Rassaf T, Mahabadi AA. Epicardial adipose tissue and culprit lesions in acute chest pain. The EPIC-ACS study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The amount of epicardial adipose tissue (EAT) is associated with prevalent and incident myocardial infarction. However, clinical studies, specifically designed to determine, how the assessment of EAT can affect patient management, are lacking. Within Epicardial adipose tissue thickness PredIcts obstructive Coronary artery disease in Acute Coronary Syndrome patients (EPIC-ACS) study we tested the hypothesis that EAT quantification improves the prediction of the presence of culprit lesions in patients presenting with acute chest pain to the emergency department.
Methods
In this observational cohort study, we prospectively included consecutive patients presenting to the emergency department with acute chest pain suggestive of acute coronary syndrome between December 2018 and August 2020. Patients with ST-elevation myocardial infarction, hemodynamic instability, or known coronary artery disease were excluded. As part of the initial workup, bedside echocardiography for quantification of EAT thickness was performed by a dedicated study physician, blinded to all patients' characteristics. Treating physicians remained unaware of the results of the EAT assessment. The primary endpoint was defined as presence of a culprit lesion, as detected in subsequent invasive coronary angiography within 90 days after initial presentation. Logistic regression analysis was performed in different models adjusted for traditional cardiovascular risk factors, cardiac biomarkers as well as established cardiovascular risk scores.
Results
Overall, 657 patients (mean age 58.06±18.04 years, 53% male) were included in our study. Patients reaching the primary endpoint had significantly more EAT than patients without culprit lesions (7.90±2.56mm vs. 3.96±1.91mm, p<0.0001, figure 1). In unadjusted regression analysis, 1mm increase in EAT thickness was associated with a nearby 2-fold increased odds of the presence of culprit lesions [1.98 (1.77–2.21), p<0.0001]. Effect sizes remained stable and highly significant, when controlling for age, gender, and BMI as well as when ancillary controlling for traditional cardiovascular risk factors and cardiac biomarkers [1.87 (1.64–2.12), p<0.0001]. Effect sizes for the association of EAT with presence of culprit lesions were similar in troponin-positive [1.85 (1.5–2.28), p<0.0001] and troponin-negative acute chest pain [1.94 (1.66–2.26), p<0.0001; p-value for interaction: 0.24]. Adding EAT to a multivariable model of GRACE score, cardiac biomarkers and traditional risk factors significantly improved the area under the receiver operating characteristics curve (0.759 to 0.901, p<0.0001).
Conclusion
EAT strongly and independently predicts the presence of culprit lesions in patients presenting with acute chest pain to the emergency department. Our results suggest that the bedside echocardiographic assessment including the quantification of EAT may improve diagnostic algorithms of patients with acute chest pain.
Funding Acknowledgement
Type of funding sources: None. Distribution of EAT thickness
Collapse
Affiliation(s)
- S Hendricks
- University Hospital Essen, West German Heart and Vascular Center Essen, Essen, Germany
| | - A Roggel
- University Hospital Essen, West German Heart and Vascular Center Essen, Essen, Germany
| | - I Dykun
- University Hospital Essen, West German Heart and Vascular Center Essen, Essen, Germany
| | - B Balcer
- University Hospital Essen, West German Heart and Vascular Center Essen, Essen, Germany
| | - F Al-Rashid
- University Hospital Essen, West German Heart and Vascular Center Essen, Essen, Germany
| | - M Totzeck
- University Hospital Essen, West German Heart and Vascular Center Essen, Essen, Germany
| | - J Risse
- University Hospital of Essen (Ruhr), Center of Emergency Medicine, Essen, Germany
| | - C Kill
- University Hospital of Essen (Ruhr), Center of Emergency Medicine, Essen, Germany
| | - T Rassaf
- University Hospital Essen, West German Heart and Vascular Center Essen, Essen, Germany
| | - A A Mahabadi
- University Hospital Essen, West German Heart and Vascular Center Essen, Essen, Germany
| |
Collapse
|
6
|
Fehrenbacher K, Apel C, Bertsch D, van der Giet MS, van der Giet S, Grass M, Gschwandtl C, Heussen N, Hundt N, Kühn C, Morrison A, Müller-Ost M, Müller-Tarpet M, Porath S, Risse J, Schmitz S, Schöffl V, Timmermann L, Wernitz K, Küpper T. Temporary threshold shift after noise exposure in hypobaric hypoxia at high altitude: results of the ADEMED expedition 2011. Int Arch Occup Environ Health 2021; 94:1191-1199. [PMID: 34023963 PMCID: PMC8292300 DOI: 10.1007/s00420-021-01715-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Accepted: 08/29/2020] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To evaluate whether there is an increased risk for noise-induced hearing loss at high altitude rsp. in hypobaric hypoxia. METHODS Thirteen volunteers got standard audiometry at 125, 250, 500, 750, 1000, 1500, 2000, 3000, 4000, 6000, and 8000 Hz before and after 10 min of white noise at 90 dB. The system was calibrated for the respective altitude. Measurements were performed at Kathmandu (1400 m) and at Gorak Shep (5300 m) (Solo Khumbu/Nepal) after 10 days of acclimatization while on trek. Temporary threshold shift (TTS) was analyzed by descriptive statistics and by factor analysis. RESULTS TTS is significantly more pronounced at high altitudes. Acclimatization does not provide any protection of the inner ear, although it increases arterial oxygen saturation. CONCLUSION The thresholds beyond which noise protection is recommended (> 80 dB) or necessary (> 85 dB) are not sufficient at high altitudes. We suggest providing protective devices above an altitude of 1500 m ("ear threshold altitude") when noise level is higher than 75 dB and using them definitively above 80 dB. This takes the individual reaction on hypobaric hypoxia at high altitude into account.
Collapse
Affiliation(s)
- K Fehrenbacher
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - C Apel
- Department of Dental Preservation, Parodontology and Preventive Dentistry, RWTH Aachen Technical University, Aachen, Germany
| | - D Bertsch
- Department of Cardiology, Catholic Hospital Marienhof, Koblenz, Germany
| | - M S van der Giet
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - S van der Giet
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - M Grass
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - C Gschwandtl
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - N Heussen
- Department of Medical Statistics, RWTH Aachen Technical University, Aachen, Germany
- Medical School, Sigmund Freud Private University, Vienna, Austria
| | - N Hundt
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - C Kühn
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - A Morrison
- Royal Free London NHS Foundation Trust, London, UK
| | - M Müller-Ost
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - M Müller-Tarpet
- Department of Technical Acoustics, RWTH Aachen University, Aachen, Germany
| | - S Porath
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - J Risse
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - S Schmitz
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - V Schöffl
- Medical Commission of the Union Internationale des Associations d'Alpinisme (UIAA MedCom), Bern, Switzerland
- Department of Sports Medicine-Sports Orthopaedics, Klinikum Bamberg, Bamberg, Germany
- Department of Trauma Surgery, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - L Timmermann
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - K Wernitz
- Department of Dental Preservation, Parodontology and Preventive Dentistry, RWTH Aachen Technical University, Aachen, Germany
| | - T Küpper
- Institute of Occupational and Social Medicine, RWTH Aachen Technical University, Pauwelsstr. 30, 52074, Aachen, Germany.
- Medical Commission of the Union Internationale des Associations d'Alpinisme (UIAA MedCom), Bern, Switzerland.
| |
Collapse
|
7
|
Zieminski P, Risse J, Legrand A, Dufrost V, Bal L, Settembre N, Malikov S, Jeunemaitre X, Wahl D, Zuily S. Vascular manifestations and kyphoscoliosis due to a novel mutation of PLOD1 gene. Acta Cardiol 2021; 76:557-558. [PMID: 32746767 DOI: 10.1080/00015385.2020.1802904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Piotr Zieminski
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
- Inserm, UMR_S 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Jessie Risse
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
- Inserm, UMR_S 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Anne Legrand
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Centre de Référence des Maladies Vasculaires Rares, Paris, France
- Inserm, U970, Paris Cardiovascular Research Centre, Paris, France
- Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Virginie Dufrost
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
- Inserm, UMR_S 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Laurence Bal
- Timone Aortic Center, Department of Vascular Surgery, La Timone Hospital, Marseille, France
| | - Nicla Settembre
- Inserm, UMR_S 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France
- Department of Vascular Surgery, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
| | - Sergueï Malikov
- Inserm, UMR_S 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France
- Department of Vascular Surgery, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
| | - Xavier Jeunemaitre
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Centre de Référence des Maladies Vasculaires Rares, Paris, France
- Inserm, U970, Paris Cardiovascular Research Centre, Paris, France
- Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Denis Wahl
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
- Inserm, UMR_S 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Stéphane Zuily
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
- Inserm, UMR_S 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| |
Collapse
|
8
|
Zuily S, de Laat B, Guillemin F, Kelchtermans H, Magy-Bertrand N, Desmurs-Clavel H, Lambert M, Poindron V, de Maistre E, Dufrost V, Risse J, Shums Z, Norman GL, de Groot PG, Lacolley P, Lecompte T, Regnault V, Wahl D. Anti–Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study. J Appl Lab Med 2020; 5:1242-1252. [DOI: 10.1093/jalm/jfaa072] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2020] [Accepted: 04/24/2020] [Indexed: 11/13/2022]
Abstract
Abstract
Background
Antibodies binding to domain I of β2-glycoprotein I (aDI) and activated protein C (APC) resistance are associated with an increased risk of thrombosis in cross-sectional studies. The objective of this study was to assess their predictive value for future thromboembolic events in patients with antiphospholipid antibodies (aPL) or antiphospholipid syndrome.
Methods
This prospective multicenter cohort study included consecutive patients with aPL or systemic lupus erythematosus. We followed 137 patients (43.5 ± 15.4 year old; 107 women) for a mean duration of 43.1 ± 20.7 months.
Results
We detected aDI IgG antibodies by ELISA in 21 patients. An APC sensitivity ratio (APCsr) was determined using a thrombin generation–based test. The APCsr was higher in patients with anti–domain I antibodies demonstrating APC resistance (0.75 ± 0.13 vs 0.48 ± 0.20, P < 0.0001). In univariate analysis, the hazard ratio (HR) for thrombosis over time was higher in patients with aDI IgG (3.31 [95% CI, 1.15–9.52]; P = 0.03) and patients with higher APC resistance (APCsr >95th percentile; HR, 6.07 [95% CI, 1.69–21.87]; P = 0.006). A sensitivity analysis showed an increased risk of higher aDI IgG levels up to HR 5.61 (95% CI, 1.93–16.31; P = 0.01). In multivariate analysis, aDI IgG (HR, 3.90 [95% CI, 1.33–11.46]; P = 0.01) and APC resistance (HR, 4.98 [95% CI, 1.36–18.28]; P = 0.02) remained significant predictors of thrombosis over time.
Conclusions
Our study shows that novel tests for antibodies recognizing domain I of β2-glycoprotein I and functional tests identifying APC resistance are significant predictors of thrombosis over time and may be useful for risk stratification.
Collapse
Affiliation(s)
- Stephane Zuily
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
- Inserm, U1116, Nancy, France
- Nancy University, Nancy, France
- University of Lorraine, Nancy, France
| | - Bas de Laat
- Synapse Research Institute, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Francis Guillemin
- University of Lorraine, Nancy, France
- Inserm, CIC-EC CIE1433, Nancy, France
| | - Hilde Kelchtermans
- Synapse Research Institute, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands
| | | | | | - Marc Lambert
- CHRU de Lille, Department of Internal Medicine, Lille, France
| | - Vincent Poindron
- CHU de Strasbourg, Internal Medicine and Clinical Immunology Department, Strasbourg, France
| | | | - Virginie Dufrost
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
- Inserm, U1116, Nancy, France
- Nancy University, Nancy, France
- University of Lorraine, Nancy, France
| | - Jessie Risse
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
- Inserm, U1116, Nancy, France
- Nancy University, Nancy, France
- University of Lorraine, Nancy, France
| | - Zakera Shums
- CHU de Dijon, Hematology Department, Dijon, France
| | | | - Philip G de Groot
- Synapse Research Institute, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands
- Clinical Chemistry and Haematology, University Medical Centre (UMC) Utrecht, Utrecht, The Netherlands
| | - Patrick Lacolley
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
- Inserm, U1116, Nancy, France
- Nancy University, Nancy, France
- University of Lorraine, Nancy, France
| | - Thomas Lecompte
- Nancy University Hospital, Hematology Laboratory, Nancy, France
| | - Véronique Regnault
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
- Inserm, U1116, Nancy, France
- Nancy University, Nancy, France
- University of Lorraine, Nancy, France
| | - Denis Wahl
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France
- Inserm, U1116, Nancy, France
- Nancy University, Nancy, France
- University of Lorraine, Nancy, France
| |
Collapse
|
9
|
Gracia S, Miserey G, Risse J, Abbadie F, Auvert JF, Chauzat B, Combes P, Creton D, Creton O, Da Mata L, Diard A, Giordana P, Josnin M, Keïta-Perse O, Lasheras A, Ouvry P, Pichot O, Skopinski S, Mahé G. Update of the SFMV (French society of vascular medicine) guidelines on the conditions and safety measures necessary for thermal ablation of the saphenous veins and proposals for unresolved issues. J Med Vasc 2020; 45:130-146. [PMID: 32402427 DOI: 10.1016/j.jdmv.2020.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Venous insufficiency is a very common disease affecting about 25% of the French population (if we combine all stages of its progression). It is a complex disease and its aetiology has not yet been fully elucidated. Some of its causes are well known, such as valvular dysfunction, vein wall defect, and the suctioning effect common to all varicose veins. These factors are generally associated and together lead to dysfunction of one or more of the saphenous veins. Saphenous vein dysfunction is revealed by ultrasound scan, a reflux lasting more than 0.5 seconds indicating venous incompetence. The potential consequences of saphenous vein dysfunction over time include: symptoms (heaviness, swellings, restlessness, cramps, itching of the lower limbs), acute complications (superficial venous thrombosis, varicose bleeding), chronic complications (changes in skin texture and colour, stasis dermatitis, eczema, vein atresia, leg ulcer), and appearance of unaesthetic varicose veins. It is not possible to repair an incompetent saphenous vein. The only therapeutic options at present are ultrasound-guided foam sclerotherapy, physical removal of the vein (saphenous stripping), or its thermal ablation (by laser or radiofrequency treatment), the latter strategy having now become the gold standard as recommended by international guidelines. Recommendations concerning thermal ablation of saphenous veins were published in 2014 by the Société française de médecine vasculaire. Our society has now decided to update these recommendations, taking this opportunity to discuss unresolved issues and issues not addressed in the original guidelines. Thermal ablation of an incompetent saphenous vein consists in destroying this by means of a heating element introduced via ultrasound-guided venous puncture. The heating element comprises either a laser fibre or a radiofrequency catheter. The practitioner must provide the patient with full information about the procedure and obtain his/her consent prior to its implementation. The checklist concerning the interventional procedure issued by the HAS should be validated for each patient (see the appended document).
Collapse
Affiliation(s)
- S Gracia
- Clinique de l'Atlantique, 17138 Puilboreau-La Rochelle, France.
| | - G Miserey
- Cabinet de Médecine Vasculaire, 78120 Rambouillet, France
| | - J Risse
- Hôpital Robert-Pax, 57200 Sarreguemines, France
| | - F Abbadie
- Hopital de Vichy, 03200 Vichy, France
| | - J F Auvert
- Cabinet de Médecine Vasculaire, 28100 Dreux, France
| | - B Chauzat
- Cabinet de Médecine Vasculaire, 24100 Bergerac, France
| | - P Combes
- Cabinet de Médecine Vasculaire, 64200 Biarritz, France
| | - D Creton
- Clinique Ambroise Paré, 54100 Nancy, France
| | - O Creton
- Hôpital Privé des Côtes d'Armor, 22190 Plérin, France
| | - L Da Mata
- Service d'Anesthésie et Réanimation Chirurgicale, Centre Hospitalier Universitaire de Nantes, 44000 Nantes, France
| | - A Diard
- Clinique Sainte Anne, 33210 Langon, France
| | - P Giordana
- Service de Chirurgie Vasculaire, Centre Hospitalier Universitaire de Nice, 06000 Nice, France
| | - M Josnin
- Clinique Saint-Charles, 85000 La Roche sur Yon, France
| | - O Keïta-Perse
- Centre Hospitalier Princesse Grace, Service Epidémiologie et Hygiène Hospitalière, 98000 Monaco, Monaco
| | - A Lasheras
- Service d'Hygiène Hospitalière, Centre Hospitalier Universitaire de Bordeaux, 33000 Bordeaux, France
| | - P Ouvry
- Cabinet de Médecine Vasculaire, 76550 Saint-Aubin-sur-Scie, France
| | - O Pichot
- Centre de Médecine Vasculaire, 38000 Grenoble, France
| | - S Skopinski
- Service de Médecine Vasculaire Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, 33000 Bordeaux, France
| | - G Mahé
- Unité de Médecine Vasculaire, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France
| |
Collapse
|
10
|
Abstract
Purpose: Worldwide, hypertension awareness remains largely insufficient. This is particularly true in some population subgroups with a low socioeconomic status or in young adults who have limited interactions with healthcare systems. Performing Blood Pressure (BP) screening in non-conventional settings, such as in barbershops, has been suggested by a number of American authors. Whether this approach is feasible in Europe or in North Africa has not been evaluated, however. We, therefore, undertook a study to assess the value of BP screening at hairdressers in France and in Morocco.Materials and Methods: This was a prospective multicenter feasibility study. Twenty-three hairdressers in France and six in Morocco participated in the study. After being provided the relevant information, all consenting customers aged over 18 years were included. Three BP measurements were performed by the customers themselves using a validated Omron M7 automatic BP device connected to a printer.Results: In France, 1025 subjects were enrolled, while 300 subjects participated in Morocco. Three hundred and seventy French participants (36%) had an elevated BP. Among the subjects claiming to be normotensive or who did not know their hypertension status, 31.7% had a BP ≥ 135/85 mmHg. Only 42% of the subjects with an elevated BP contacted their physician within 3 months, although hypertension was confirmed in ¾ of them. In Morocco, the participants were older, with only 11.7% of the subjects aged <50 years. They more frequently had unknown elevated BP values (71.9%). The rate of BP monitoring in known hypertensive individuals was 42.7% in France and 17.1% in Morocco. The procedure was very well accepted and considered to be useful in both countries.Conclusion: BP screening at hairdressers is feasible and well-accepted, although it does suffer somewhat from a relatively low efficacy.
Collapse
Affiliation(s)
- J M Boivin
- Department of General Medicine, Faculty of Medicine of Nancy, University of Lorraine, Vandoeuvre, France.,CIC-P Pierre Drouin, Inserm-CHRU of Nancy, Vandoeuvre, France
| | - J Risse
- Department of General Medicine, Faculty of Medicine of Nancy, University of Lorraine, Vandoeuvre, France
| | - E Laurière
- Department of General Medicine, Faculty of Medicine of Nancy, University of Lorraine, Vandoeuvre, France
| | - M Burnier
- Service of Nephrology and Hypertension, University Hospital, Lausanne, Switzerland
| |
Collapse
|
11
|
Zuily S, Phialy L, Sevim E, Germain E, Unlu O, Dufrost V, Risse J, Clerc-Urmès I, Baumann C, Berman JR, Lockshin MD, Wahl D, Erkan D. Impact of antiphospholipid syndrome iBook on medical students' improvement of knowledge: An international randomized controlled study. Eur J Rheumatol 2019; 6:207-211. [PMID: 31657703 DOI: 10.5152/eurjrheum.2019.19030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 05/09/2019] [Indexed: 11/22/2022] Open
Abstract
OBJECTIVE iBook on Antiphospholipid Syndrome (APS) did not exist before our work, and hence the utility of an Apple iBook as a teaching method in APS for medical students has never been assessed. Our objective was to evaluate medical students' improvement of knowledge and satisfaction with an interactive APS iBook, in comparison with conventional teaching methods. METHODS An iBook designer with the guidance of a medical team developed the APS iBook in both French and English. Second-year medical students, naïve of APS knowledge, were enrolled from two institutions. For the "teaching intervention", participants were randomly assigned to three groups: a) APS iBook with interactive capability; b) printed copy of the APS iBook material; and c) classroom lecture presentation of the APS iBook material by a physician-scientist experienced in APS. The participants filled a standardized medical questionnaire about APS before and after teaching interventions to determine the relative change of knowledge. Participants were asked to fill out a standardized satisfaction survey. After 20 weeks of the intervention, recall capability of students was tested. RESULTS A total of 233 second-year medical students were enrolled (iBook group: 73; print group: 79, and lecture group: 81). Relative change of knowledge was not different between the iBook group and the printed material group; additionally, it was significantly higher in the lecture group than the two other methods. Satisfaction was significantly higher in both the lecture and the iBook groups than the print group, on several dimensions including overall quantitative satisfaction, subjective enhanced knowledge, interactivity, quality of content, comprehensibility, and pleasure of learning. Recall capability of students (n=109, 47%) was not significantly different among groups. CONCLUSION The APS iBook is as effective as printed material in improving medical student's knowledge, although a classroom lecture was the most effective method when compared to self-learning methods. Among self-learning methods, medical students are more satisfied with the APS iBook, whereas the recall capability was not different among groups. These results suggest that the APS iBook will help medical students in their curriculum and increase the awareness of APS among the community.
Collapse
Affiliation(s)
- Stephane Zuily
- Université de Lorraine, Faculty of Medicine, F-54000 Nancy, France.,CHRU Nancy, Vascular Medicine Division and Regional Competence Center for Rare Systemic and Autoimmune Diseases, F-54000 Nancy, France
| | - Laurent Phialy
- Université de Lorraine, Faculty of Medicine, F-54000 Nancy, France
| | - Ecem Sevim
- Hospital for Special Surgery, New York, NY, USA
| | - Eloïse Germain
- Université de Lorraine, Faculty of Medicine, F-54000 Nancy, France
| | - Ozan Unlu
- Weill Cornell Medicine, New York, NY, USA
| | - Virginie Dufrost
- Université de Lorraine, Faculty of Medicine, F-54000 Nancy, France.,CHRU Nancy, Vascular Medicine Division and Regional Competence Center for Rare Systemic and Autoimmune Diseases, F-54000 Nancy, France
| | - Jessie Risse
- Université de Lorraine, Faculty of Medicine, F-54000 Nancy, France.,CHRU Nancy, Vascular Medicine Division and Regional Competence Center for Rare Systemic and Autoimmune Diseases, F-54000 Nancy, France
| | - Isabelle Clerc-Urmès
- CHRU de Nancy, Platform of Clinical Research Support PARC (MDS unity), F-54000 Nancy, France
| | - Cédric Baumann
- CHRU de Nancy, Platform of Clinical Research Support PARC (MDS unity), F-54000 Nancy, France
| | - Jessica R Berman
- Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA
| | - Michael D Lockshin
- Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA
| | - Denis Wahl
- Université de Lorraine, Faculty of Medicine, F-54000 Nancy, France.,CHRU Nancy, Vascular Medicine Division and Regional Competence Center for Rare Systemic and Autoimmune Diseases, F-54000 Nancy, France
| | - Doruk Erkan
- Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA
| |
Collapse
|
12
|
Creton O, Risse J, Creton D. Conservative treatment of anastomosing incompetent thigh perforators by selective ablation of the distal incompetent greater saphenous trunk: Feasibility and short-term Results. Ann Vasc Surg 2019. [DOI: 10.1016/j.avsg.2019.08.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, Wahl D, Zuily S. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 2018; 17:1011-1021. [DOI: 10.1016/j.autrev.2018.04.009] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2018] [Accepted: 04/22/2018] [Indexed: 02/05/2023]
|
14
|
Risse J, Mandry D, Settembre N, Vigouroux C, Claudin M, Tsintzila G, Huttin O, Malikov S, Zuily S, Wahl D. Dramatic Response to Tocilizumab Before Emergency Surgery in Severe Active Takayasu Disease. Circ Cardiovasc Imaging 2018; 9:CIRCIMAGING.116.004819. [PMID: 27406844 DOI: 10.1161/circimaging.116.004819] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jessie Risse
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.).
| | - Damien Mandry
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| | - Nicla Settembre
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| | - Charlène Vigouroux
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| | - Marine Claudin
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| | - Georgia Tsintzila
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| | - Olivier Huttin
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| | - Sergueï Malikov
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| | - Stéphane Zuily
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| | - Denis Wahl
- From the Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases (J.R., S.Z., D.W.), Departments of Radiology (D.M.), Vascular Surgery (N.S., S.M.), Pathology (C.V.), Nuclear Medicine (M.C.), and Cardiology (O.H.), CHRU de Nancy, France; INSERM, U1116, Nancy, France (J.R., S.Z., D.W.); Lorraine University School of Medicine, Nancy, France (J.R., D.M., N.S., D.W., S.M., S.Z.); France; INSERM, U947, Nancy, France (D.M.); Department of Cardiology, CHR de Metz-Thionville, Nancy, France (G.T.)
| |
Collapse
|
15
|
Dufrost V, Risse J, Wahl D, Zuily S. Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome: reply. Rheumatology (Oxford) 2018; 57:939-940. [DOI: 10.1093/rheumatology/kex464] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 10/27/2017] [Indexed: 12/18/2022] Open
Affiliation(s)
- Virginie Dufrost
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, France
| | - Jessie Risse
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, France
- Inserm UMR_S 1116 at Lorraine University, Nancy, France
| | - Denis Wahl
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, France
- Inserm UMR_S 1116 at Lorraine University, Nancy, France
| | - Stéphane Zuily
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, France
- Inserm UMR_S 1116 at Lorraine University, Nancy, France
| |
Collapse
|
16
|
Reichmann K, Yong-Hing C, Damm M, Risse J, Ahmadzadehfar H, Logvinski T, Guhlke S, Biersack HJ, Sabet A, Ezziddin S. Early prediction of tumour response to PRRT. Nuklearmedizin 2018; 52:170-7. [DOI: 10.3413/nukmed-0581-13-05] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Accepted: 07/01/2013] [Indexed: 01/05/2023]
Abstract
Summary[177Lu-DOTA0, Tyr3]-octreotate (177Lu-octreotate) in peptide receptor radionuclide therapy (PRRT) offers direct intra-therapeutic dosimetry. The aim of this study was to compare tumour and non-tumour parameters and assess intra-individual variations. Patients, methods: Retrospective analysis of 53 consecutive PRRT treatment cycles (mean activity of 7.53 ± 0.46 GBq 177Lu-octreotate, intended four cycles at intervals of 10–14 weeks, standard nephroprotection) in 27 GEP NET patients. Extended planar dosimetry with serial wholebody imaging on selected, non-superimposed tumour and non-tumour regions; liver (LM), bone (BM), and other (OM) metastases. The per-cycle variation was compared with posttreatment response (CT/MRI three months post-treatment, modified SWOG criteria). Results: Residence time in tumor lesions (133–147 h) exceeded that in kidneys (93 h). Tumour-to-kidney absorbed dose ratios ranged from 14 to 28 (LM, BM, OM). Intra-individual per-cycle dose variation was insignificant for kidneys, but significant for metastases (LM, BM, and OM; p < 0.05). The mean per-cycle decrease of tumour absorbed dose (_D/A0[%]) was linked to morphologic response after PRRT. A mean decrease of >20% was predictive of a partial or minor remission in all 11 evaluable patients, while absent significant dose reduction indicated stable or progressive disease in 4/5 patients. The dose decrease was unrelated to volume effects and also observed for BM. Conclusion: Besides confirmation of a favourable tumour-to-kidney parameter relation for 177Lu-octreotate, stepwise intra-lesional comparison seems to imply a prognostic impact of tumor dosimetry: The early per-cycle change _D/A0 between treatment cycles may predict the outcome after PRRT. Larger studies are needed to confirm this finding.
Collapse
|
17
|
Abstract
PURPOSE OF REVIEW Antiphospholipid antibody syndrome (APS) is characterized primarily by thrombosis and pregnancy morbidity. Chronic vascular lesions can also occur. While the underlying mechanisms of these vascular lesions are not entirely known, there have been multiple theories describing the potential process of vasculopathy in APS and the various clinical manifestations associated with it. RECENT FINDINGS Recently, it has been demonstrated that endothelial proliferation in kidneys can be explained by the activation of the mammalian target of rapamycin complex (mTORC) pathway by antiphospholipid antibodies (aPL). These data support the existence of an APS-related vasculopathy in different locations which can explain-in part-the different manifestations of APS. This review focuses on the various manifestations of APS as a result of APS-related vasculopathy, as well as pathophysiology, current screening, and treatment options for clinicians to be aware of.
Collapse
Affiliation(s)
- Salma Siddique
- Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, 535 East 70th Street, New York, NY, 10021, USA.
| | - Jessie Risse
- CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Inserm U1116 at Lorraine University, Nancy, France
| | - Guillaume Canaud
- Université Paris Descartes, Sorbonne Paris Cité; Inserm U1151, Institut Necker-Enfants Malades; Service de Néphrologie Transplantation Adultes, Hôpital Necker-Enfants Malades, Paris, France
| | - Stéphane Zuily
- CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Inserm U1116 at Lorraine University, Nancy, France
| |
Collapse
|
18
|
Dufrost V, Risse J, Malgras A, Barraud H, Jaussaud R, Zuily S, Wahl D. Unexpected Cause of Bleeding. Am J Med 2017; 130:e387-e388. [PMID: 28389311 DOI: 10.1016/j.amjmed.2017.03.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 02/28/2017] [Accepted: 03/01/2017] [Indexed: 10/19/2022]
Affiliation(s)
- Virginie Dufrost
- Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, France
| | - Jessie Risse
- Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, France; Inserm Unité mixte de recherche en santé 1116 at Lorraine University, Nancy, France
| | | | - Hélène Barraud
- Department of Hepatology and Gastroenterology, CHRU de Nancy, France
| | - Roland Jaussaud
- Department of Internal Medicine and Clinical Immunology, Regional Competence Center for Rare and Systemic Autoimmune Disease, CHRU de Nancy, France
| | - Stéphane Zuily
- Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, France; Inserm Unité mixte de recherche en santé 1116 at Lorraine University, Nancy, France
| | - Denis Wahl
- Vascular Medicine Division, Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, France; Inserm Unité mixte de recherche en santé 1116 at Lorraine University, Nancy, France.
| |
Collapse
|
19
|
Abstract
We report an original case of reversible antiphospholipid syndrome (APS) due to minocycline in a young male patient who experienced recurrent strokes while taking minocycline. He started minocycline therapy (50 mg twice daily) at 15 years old for acne. After three years of treatment, the patient experienced a lateral medullary syndrome. He was treated with aspirin while minocycline was continued. Eighteen months later, the patient complained about horizontal binocular diplopia. MRI revealed an infarct of the oculomotor nerve nucleus. Laboratory investigations revealed high titers of anti-beta 2 glycoprotein 1 (antiβ2GP1) antibodies of 470 U/ml (normal range <15 U/ml) and antiphosphatidylethanolamine antibodies of 137.4 U/ml (normal range <18 U/ml). Other laboratory tests were normal. Six weeks after discontinuation of minocycline, anti-β2GP1 antibodies decreased to 335 U/ml and to 36 U/ml at six months and then remained negative for six years. Many drugs have been considered as possibly causing APS but only in a limited number of patients. To our knowledge this is the first case of drug-induced APS with complete disappearance of high titers of anti-β2GP1 antibodies after minocycline withdrawal. This case also illustrates the need to monitor the levels of antiphospholipid antibodies, even though initial values are high and confirmed after 12 weeks.
Collapse
Affiliation(s)
- J Risse
- 1 CHRU de Nancy, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France.,2 Inserm, UMR S 1116, Lorraine University, Nancy, France
| | - M Vieira
- 3 Hospital Universitario Clementino Fraga Filho, Department of Internal Medicine, Rio de Janeiro, Brazil
| | - F Beuret
- 4 CHRU de Nancy, Department of Diagnostic and Therapeutic Neuroradiology, Nancy, France
| | - N Petitpain
- 5 CHRU de Nancy, Regional Center of Pharmacovigilance, Department of Clinical Pharmacology and Toxicology, Nancy, France
| | - S Zuily
- 1 CHRU de Nancy, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France.,2 Inserm, UMR S 1116, Lorraine University, Nancy, France
| | - D Wahl
- 1 CHRU de Nancy, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, France.,2 Inserm, UMR S 1116, Lorraine University, Nancy, France
| |
Collapse
|
20
|
Decker P, Galland J, Mohamed S, Risse J, Wahl D. Des orteils pourpres révélant un POEMS syndrome. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
21
|
Dufrost V, Risse J, Kirchner S, Zuily S, Wahl D. Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome. Rheumatology (Oxford) 2017; 56:1433-1434. [DOI: 10.1093/rheumatology/kex086] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Risse J, Busato T, Dufrost V, Perri M, Zuily S, Wahl D. [Development of an objective structured clinical examination (OSCE) for evaluating clinical competence in vascular medicine]. J Med Vasc 2017; 42:141-147. [PMID: 28705402 DOI: 10.1016/j.jdmv.2017.02.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Accepted: 01/20/2017] [Indexed: 10/19/2022]
Abstract
OBJECTIVES Vascular medicine is now a clinical specialty in France. During their studies, students will acquire clinical reasoning in addition to technical skills. An Objective Structured Clinical Examination (OSCE) is considered as the gold standard for evaluating clinical competence. Our main objective was to evaluate the feasibility and acceptability of OSCE for the evaluation of students, secondarily their performance. METHODS Three representative clinical cases of the specialty were developed. The OSCE consisted of a sequence of clinical situations presented in three stations of 7minutes each. The role of the simulated patient was played by medical students. At the end of the OSCE, observers and students completed the evaluation form. We compared the performances between junior and senior vascular medicine students. Written questionnaires were used to measure OSCE satisfaction. RESULTS We were able to develop and organize this examination without difficulties. Fifteen students were evaluated. All participants agreed that the clinical situations were representative of vascular medicine practice, the cases were realistic and standardized patients were convincing. The performance of senior students was statistically higher than junior students in one case. DISCUSSION Our study demonstrates the feasibility and acceptability of the OSCE in students in vascular medicine. The small number of stations and candidates requires further studies on a larger scale to evaluate their performance.
Collapse
Affiliation(s)
- J Risse
- Service de médecine vasculaire et centre de compétence régional des maladies vasculaires rares et systémiques auto-immunes, CHRU de Nancy, 54511 Vandoeuvre-lès-Nancy cedex, France; Inserm, UMR S 1116, université de Lorraine, 54000 Nancy, France.
| | - T Busato
- Service de médecine vasculaire et centre de compétence régional des maladies vasculaires rares et systémiques auto-immunes, CHRU de Nancy, 54511 Vandoeuvre-lès-Nancy cedex, France
| | - V Dufrost
- Service de médecine vasculaire et centre de compétence régional des maladies vasculaires rares et systémiques auto-immunes, CHRU de Nancy, 54511 Vandoeuvre-lès-Nancy cedex, France
| | - M Perri
- Service de médecine vasculaire et centre de compétence régional des maladies vasculaires rares et systémiques auto-immunes, CHRU de Nancy, 54511 Vandoeuvre-lès-Nancy cedex, France
| | - S Zuily
- Service de médecine vasculaire et centre de compétence régional des maladies vasculaires rares et systémiques auto-immunes, CHRU de Nancy, 54511 Vandoeuvre-lès-Nancy cedex, France; Inserm, UMR S 1116, université de Lorraine, 54000 Nancy, France
| | - D Wahl
- Service de médecine vasculaire et centre de compétence régional des maladies vasculaires rares et systémiques auto-immunes, CHRU de Nancy, 54511 Vandoeuvre-lès-Nancy cedex, France; Inserm, UMR S 1116, université de Lorraine, 54000 Nancy, France
| |
Collapse
|
23
|
Dufrost V, Risse J, Zuily S, Wahl D. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep 2016; 18:74. [DOI: 10.1007/s11926-016-0623-7] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Broly E, Risse J, Maschino F, Wahl D. Cardiac Tamponade Due to Actinomyces odontolyticus Originating From a Dentigerous Cyst. J Oral Maxillofac Surg 2016; 74:2453-2456. [PMID: 27311847 DOI: 10.1016/j.joms.2016.05.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Revised: 05/13/2016] [Accepted: 05/13/2016] [Indexed: 11/18/2022]
Abstract
This report describes a rare case of pericardial effusion owing to Actinomyces odontolyticus in a 52-year-old woman that originated from a dentigerous cyst, which developed on the distal aspect of a lower left third molar. The cyst had remained asymptomatic for a long period, with no specific functional complications. This is the first case report of a patient with acute pericarditis in which the same strain of A odontolyticus was detected in an asymptomatic dentigerous cyst and in the pericardial fluid.
Collapse
Affiliation(s)
- Elyette Broly
- Resident, Department of Oral Pathology, Oral Medicine and Oral Surgery, Dental Faculty, University Hospital of Nancy, Nancy, France.
| | - Jessie Risse
- Hospital Practioner, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France
| | - François Maschino
- Hospital Practitioner, Department of Oral Pathology, Oral Medicine and Oral Surgery, Dental Faculty, University Hospital of Nancy, Nancy, France
| | - Denis Wahl
- University Professor and Hospital Practitioner, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France
| |
Collapse
|
25
|
Moulinet T, Risse J, Frederic M, Blum A, Zuily S, Wahl D. Successful treatment with thrombolysis and stent in acute limb ischemia complicating antiphospholipid syndrome. Int J Cardiol 2016; 212:285-6. [PMID: 27057937 DOI: 10.1016/j.ijcard.2016.03.139] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Accepted: 03/19/2016] [Indexed: 11/29/2022]
Affiliation(s)
- Thomas Moulinet
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, CHU Nancy, Vandoeuvre-les Nancy, Nancy 54511, France.
| | - Jessie Risse
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, CHU Nancy, Vandoeuvre-les Nancy, Nancy 54511, France; INSERM UMR_S 1116, France; Université de Lorraine, Nancy, France
| | - Muriel Frederic
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, CHU Nancy, Vandoeuvre-les Nancy, Nancy 54511, France
| | - Alain Blum
- Université de Lorraine, Nancy, France; Service d'imagerie Guilloz, Hôpital Central, CHU Nancy, France
| | - Stéphane Zuily
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, CHU Nancy, Vandoeuvre-les Nancy, Nancy 54511, France; INSERM UMR_S 1116, France; Université de Lorraine, Nancy, France
| | - Denis Wahl
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, CHU Nancy, Vandoeuvre-les Nancy, Nancy 54511, France; INSERM UMR_S 1116, France; Université de Lorraine, Nancy, France
| |
Collapse
|
26
|
Risse J, Martin-Bertaux A, Nicolas A, Olivier P, Wahl D. Tomographie par émission de positons au 18-fluorodésoxyglucose et diagnostic de récidive de thrombose veineuse profonde. Presse Med 2016; 45:271-3. [DOI: 10.1016/j.lpm.2015.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 10/16/2015] [Accepted: 11/26/2015] [Indexed: 10/22/2022] Open
|
27
|
Luconi N, Risse J, Busato T, Galland J, Mandry D, Voilliot D, Mohamed S, Zuily S, Wahl D. Myocarditis in a young man with adult onset Still's disease successfully treated with Il-1 blocker. Int J Cardiol 2015; 189:220-2. [PMID: 25897909 DOI: 10.1016/j.ijcard.2015.04.071] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Accepted: 04/09/2015] [Indexed: 01/22/2023]
Affiliation(s)
- N Luconi
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France
| | - J Risse
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France
| | - T Busato
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France
| | - J Galland
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France
| | - D Mandry
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France
| | - D Voilliot
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France
| | - S Mohamed
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France
| | - S Zuily
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France
| | - D Wahl
- Nancy University Hospital, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Disease, Nancy, France.
| |
Collapse
|
28
|
Ezziddin S, Wilhelm K, Fimmers R, Spengler U, Palmedo H, Strunk H, Schild HH, Biersack HJ, Risse J, Ahmadzadehfar H, Habibi E. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. Nuklearmedizin 2014; 53:46-53. [DOI: 10.3413/nukmed-0610-13-07] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
SummaryThis study investigated the efficacy of 131iod- ine-labeled lipiodol (1311-lipiodol) as a palliative therapy, evaluated overall survival (OS) across Barcelona Clinic Liver Cancer (BCLC) stages, and determined the main prognostic factors influencing OS in patients with hepatocellular carcinoma (HCC). Patients, methods: We retrospectively analyzed 57 (44 men; mean age, 65.7 years; mean activity per session, 1.6 GBq; mean cumulative activity in patients with >1 sessions, 3.9 GBq) HCC patients who underwent 1311-lipiodol therapy. A majority of patients exhibited Child-Pugh class B (53.6%) disease and a good Eastern Cooperative Oncology Group performance status (0-1; 72%). Multinodular disease was observed in 87.7% patients, bilobar disease in 73%, and portal vein occlusion (PVO) in 54%. Furthermore, 21.1% patients were staged as BCLC B and 59.6 % as BCLC C. All patients were followed until death. Results: The median OS was 6.4 months, which varied significantly with disease stage (median OS for BCLC A, B, C, and D was 29.4, 12.0, 4.6, and 2.7 months, respectively; p = 0.009); Child-Pugh score and class; presence of ascites, PVO, or extrahepatic disease; largest lesion size; favourable treatment response; international normalized ratio, baseline albumin and alpha-fetopro- tein levels. Patients with a Child-Pugh A liver disease had a longer OS. Conclusion: Currently, different treatment modalities for HCC include radioembolization, transarterial chemoemboliz- ation, and systemic therapy with sorafenib; however, 1311-lipiodol therapy remains a feasible alternative for patients without a favourable response to other therapies, particularly for patients with Child-Pugh A liver cirrhosis.
Collapse
|
29
|
Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, Derow C, Dimmer E, Feuermann M, Friedrichsen A, Huntley R, Kohler C, Khadake J, Leroy C, Liban A, Lieftink C, Montecchi-Palazzi L, Orchard S, Risse J, Robbe K, Roechert B, Thorneycroft D, Zhang Y, Apweiler R, Hermjakob H. IntAct--open source resource for molecular interaction data. Nucleic Acids Res 2006; 35:D561-5. [PMID: 17145710 PMCID: PMC1751531 DOI: 10.1093/nar/gkl958] [Citation(s) in RCA: 630] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
IntAct is an open source database and software suite for modeling, storing and analyzing molecular interaction data. The data available in the database originates entirely from published literature and is manually annotated by expert biologists to a high level of detail, including experimental methods, conditions and interacting domains. The database features over 126 000 binary interactions extracted from over 2100 scientific publications and makes extensive use of controlled vocabularies. The web site provides tools allowing users to search, visualize and download data from the repository. IntAct supports and encourages local installations as well as direct data submission and curation collaborations. IntAct source code and data are freely available from .
Collapse
Affiliation(s)
- S Kerrien
- EMBL Outstation-European Bioinformatics Institute (EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
For more than 50 years now, nuclear medicine has offered therapeutic procedures in oncology. These comprise bone pain palliation in bone metastases of prostate and breast cancer. For more than 20 years now, metaiodobenzylguanidine (mIBG) has been used to treat neuroendocrine tumors. Ten years ago, somatostatin analogues such as Y-90 Dotatoc became available for the treatment of somatostatin receptor-positive tumors. The intracavitary injection of radiocolloids has been well known for 5 decades now and can be used in malignant effusions. Invasive procedures such as intra-arterial injection of I-131 lipiodol may be applied in multifocal, nonresectable hepatocellular carcinoma. Beyond that, intratumoral injection of radioisotopes may be used in cutaneous metastases. Radioimmunotherapy using labeled tumor antibodies is now also available, especially in patients with non-Hodgkin's lymphoma.
Collapse
Affiliation(s)
- H-J Biersack
- Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn.
| | | | | | | | | |
Collapse
|
31
|
Huber A, Gaffal E, Schweichel D, Distelmaier M, Textor HJ, Matthies A, Jaeger U, Risse J, Nonn S, Joe A, Mallek DV, Bieber T, Biersack HJ, Reinhardt MJ, Tüting T. Erfahrungen mit der kombinierten PET/CT-Bildgebung in der Ausbreitungsdiagnostik bei malignem Melanom. Akt Dermatol 2004. [DOI: 10.1055/s-2004-832564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
32
|
Distelmaier M, Schweichel D, Textor HJ, Matthies A, Jaeger U, Risse J, Nonn S, Joe A, von Mallek D, Bieber T, Biersack HJ, Reinhardt MJ, Tüting T. Resultate der kombinierten PET/CT-Bildgebung bei Verdacht auf Melanommetastasen. Akt Dermatol 2003. [DOI: 10.1055/s-2003-822221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Abstract
Mixed connective tissue disease is a rare disorder in childhood and seldom affects the CNS. The detection of U1-n-RNP antibodies in blood and CSF as well as speckled immunofluorescence pattern are diagnostic.
Collapse
Affiliation(s)
- F Herbst
- Zentrum für Kinderheilkunde und Jugendmedizin, Abt. Neuropädiatrie, Justus-Liebig-Universität, Giessen, Germany
| | | | | | | | | | | |
Collapse
|
34
|
Palmedo H, Rockstroh JK, Bangard M, Schliefer K, Risse J, Menzel C, Biersack HJ. Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study. Radiology 2001; 221:256-60. [PMID: 11568349 DOI: 10.1148/radiol.2211010095] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Eight patients (77 joints) with polyarthritis were treated systemically with 570 MBq (15.4 mCi) of rhenium 186 ((186)Re) hydroxyethylidenediphosphonate (HEDP). Pain and disease activity were assessed monthly. In six (75%) of eight patients, a single injection of (186)Re HEDP led to an improvement in disease activity. Systemic low-dose treatment with (186)Re HEDP can reduce pain and disease activity in patients with polyarthritis.
Collapse
Affiliation(s)
- H Palmedo
- Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
| | | | | | | | | | | | | |
Collapse
|
35
|
Tabocchini MA, Rothkamm K, Signoretti C, Risse J, Sapora O, Löbrich M. Formation and repair of DNA double-strand breaks in gamma-irradiated K562 cells undergoing erythroid differentiation. Mutat Res 2000; 461:71-82. [PMID: 10980413 DOI: 10.1016/s0921-8777(00)00041-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cellular differentiation is accompanied by gross changes in nuclear organization, metabolic pathways and gene expression characteristics. To investigate, whether the response to radiation damage is altered during cellular differentiation, we studied the formation and repair of DNA double-strand breaks in gamma-irradiated K562 erythroleukemia cells induced to differentiate by exposure to butyric acid. We applied an assay based on pulsed-field gel electrophoresis and Southern hybridization to measure break induction in several genomic restriction fragments. Pulsed-field gel electrophoresis of (14)C-labelled unrestricted DNA was used to study the rejoining of gamma-radiation-induced breaks in the whole genome. Total rejoining and joining of correct break ends in specific genomic regions was monitored by hybridization analysis of blots of unrestricted and restriction digested DNA with single-copy probes. The yields of gamma-ray-induced DNA double-strand breaks were found to decrease with differentiation by about 20%. Correct rejoining of radiation-induced breaks, as measured by the reconstitution of broken restriction fragments, was unaltered in differentiating cells compared to actively proliferating precursor cells. Total rejoining, however, appeared to be retarded in differentiating cells. The results suggest that in spite of the fundamental changes accompanying differentiation, the cellular damage response pathways are not essentially affected throughout erythroid differentiation.
Collapse
Affiliation(s)
- M A Tabocchini
- Physics Laboratory, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
| | | | | | | | | | | |
Collapse
|
36
|
Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grünwald F, Knapp FF, Biersack HJ. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000; 27:123-30. [PMID: 10755716 DOI: 10.1007/s002590050017] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
The aim of this study was to determine the maximum tolerated dose of rhenium-188 hydroxyethylidene diphosphonate (HEDP) in prostate cancer patients with osseous metastases who are suffering from bone pain. Twenty-two patients received a single injection of escalating doses of carrier-added 188Re-HEDP [1.3 GBq (35 mCi), 2.6 GBq (70 mCi), 3.3 GBq (90 mCi) and 4.4 GBq (120 mCi)]. Blood counts and biochemical parameters were measured weekly over a period of 8 weeks. Haematological toxicity (WHO grading) of grade 3 or 4 was considered unacceptable. Clinical follow-up studies including methods of pain documentation (medication, pain diary) were performed for 6 months after treatment. In the 1.3-GBq group, no haematological toxicity was observed. First haematotoxic results were noted in those patients with a dose of 2.6 GBq 188Re-HEDP. In the 3.3-GBq group, one patient showed a reversible thrombopenia of grade 1, one a reversible thrombopenia of grade 2 and three a reversible leukopenia of grade 1. In the 4.4-GBq group, thrombopenia of grades 3 and 4 was observed in one and two patients (baseline thrombocyte count <200x10(9)/l), respectively, and leukopenia of grade 3 was documented in one patient. The overall nadir of thrombopenia was at week 4. The individual, maximum percentage decrease in thrombocytes in the 1.3-, 2.6-, 3.3- and 4.4-GBq groups was 17%, 40%, 60% and 86%, respectively. In two patients, a transient increase in serum creatinine was observed (max. 1.6 mg/dl). Pain palliation was reported by 64% of patients, with a mean duration of 7.5 weeks. The response rate seemed to increase with higher doses, reaching 75% in the 4.4-GBq group. It is concluded that in prostate cancer patients, the maximum tolerated dose of 188Re-HEDP is 3.3 GBq if the baseline thrombocyte count is below 200x10(9)/l. In patients with thrombocyte counts significantly above 200x10(9)/l, a dose of 4.4 GBq might be tolerable. Thrombo- and leukopenia are the most important side-effects. Pain palliation can be achieved in 60%-75% of patients receiving a dose of 2.6 GBq or more of 188Re-HEDP. Studies in a larger patient population are warranted to evaluate further the palliative effect of 188Re-HEDP.
Collapse
Affiliation(s)
- H Palmedo
- Department of Nuclear Medicine, University of Bonn, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Palmedo H, Bender H, Dierke-Dzierzon C, Carl UM, Risse J, Krebs D, Biersack HJ. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Clin Nucl Med 1999; 24:643-8. [PMID: 10478737 DOI: 10.1097/00003072-199909000-00001] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate (HEDP) is efficient in pain palliation of disseminated bone metastases. The aim of this study was to determine whether significant pain reduction can also be achieved in breast cancer patients with Re-186 HEDP. METHODS Thirty patients with breast cancer who had multifocal painful bone metastases received a total of 38 intravenous Re-186 HEDP injections. Pain relief was assessed through daily documentation of the visual analog scale and analgesic consumption. A significant response to treatment was determined if the visual analog scale or analgesic consumption decreased significantly for at least 2 weeks. Blood counts were controlled at baseline and at weeks 4 and 8. RESULTS A response to pain therapy was observed in 60% (18 of 30) of the patients. A reversible thrombocytopenia and leukopenia of grade 2 (according to World Health Organization criteria) was found in 4 and 2 patients, respectively. CONCLUSION Patients with disseminated osseous metastases resulting from breast cancer can benefit from therapy with Re-186 HEDP.
Collapse
Affiliation(s)
- H Palmedo
- Department of Nuclear Medicine, University of Bonn, Germany
| | | | | | | | | | | | | |
Collapse
|
38
|
Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, Risse J, Biersack HJ. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39:1903-6. [PMID: 9829580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
UNLABELLED Due to a dedifferentiation of tumor cells, some thyroid carcinomas lose their capability for radioiodine (RI) concentration. This phenomenon is associated with a worse prognosis and prevents effective treatment. Retinoic acid (RA) is known to induce redifferentiation in various kinds of tumors and has been used recently in thyroid cancer. METHODS Twelve patients (9 women, 3 men) with 6 papillary, 4 follicular and 2 mixed-cell type tumors (including 4 Hurthle cell carcinomas) were treated orally with RA (dose: 1.18 +/- 0.37 mg/kg body weight) for at least 2 mo before RI therapy. None of the patients could be treated with any other modality (RI, surgery, external radiation) when RA administration was started. Initially, clinically important tumor sites did not take up significant amounts of RI. Changes of RI uptake and thyroglobulin (Tg) serum values were determined. Glucose metabolism was followed with fluorodeoxyglucose (FDG) PET imaging in 10 patients before and in 5 patients after RA treatment. RESULTS In 2 patients, a significant RI uptake was induced by RA, and in another 3 patients a faint RI uptake was achieved (responder group). In 7 patients, no change of RI uptake was observed (nonresponder group). Median Tg was increased from 105-840 microg/liter during RA therapy in the responder group, which was significantly higher than the nonresponder group (173-134 microg/liter). FDG PET was positive in all 10 patients before RA therapy. PET showed variable patterns of changes (increase/decrease/disappearance) in glucose consumption related to RA response. CONCLUSION RA can induce RI uptake in some patients with RI negative thyroid carcinoma tumor sites. Response to RA is associated with a significantly higher increase of Tg, suggesting that a restoration of Tg synthesis can be addressed as a redifferentiation parameter in these patients.
Collapse
Affiliation(s)
- F Grünwald
- Department of Nuclear Medicine and Institute for Medical Statistics, University of Bonn, Germany
| | | | | | | | | | | | | | | |
Collapse
|